Calls
8
#530
Alpha Score 48.8
Chris Irons
Financial Commentator and Author, QTR's Fringe Finance
Win Rate
42.9%
return
-0.2%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jul 23
$11.81
-0.5%
The psychedelic drug sector is an asymmetric upside opportunity. It is underfollowed, clinical trial data is positive, regulatory tailwinds are emerging (RFK Jr., FDA fast-tracking), and big pharma validation arrived with Eli Lilly's acquisition of Atai. Stocks like Compass Pathways, Definium/MindMed, and the PSI ETF stand to benefit significantly.
Pharma & Biotech
Long
Jul 23
$64.69
-0.6%
The valuation gap between the US market and the rest of the world is extreme. The US P/E multiple must contract while the rest-of-world multiple expands, driving outperformance of emerging markets (EEM) over US equities.
Equity Indexes
Long
Jul 23
$74.65
+0.7%
Gold miners have pulled back sharply while gold remains elevated. The GDX has fallen from ~120 to ~75, P/E multiples contracted significantly, and miners still extract gold at low cost. This divergence creates an attractive entry for a sector that will surge when gold rallies again.
Thematic ETFs
Long
Jul 23
$371.49
+0.0%
Gold is a long-term bull due to monetary debasement, relentless Fed printing, and a weakening dollar. After a sharp deleveraging event that initially sells off gold, the Fed will intervene with massive stimulus, sending gold to $7,500 or higher within 12-18 months.
Commodities
Long
Jul 23
$43.41
-
The psychedelic drug sector is an asymmetric upside opportunity. It is underfollowed, clinical trial data is positive, regulatory tailwinds are emerging (RFK Jr., FDA fast-tracking), and big pharma validation arrived with Eli Lilly's acquisition of Atai. Stocks like Compass Pathways, Definium/MindMed, and the PSI ETF stand to benefit significantly.
Pharma & Biotech
Long
Jul 23
$24.10
-0.7%
The psychedelic drug sector is an asymmetric upside opportunity. It is underfollowed, clinical trial data is positive, regulatory tailwinds are emerging (RFK Jr., FDA fast-tracking), and big pharma validation arrived with Eli Lilly's acquisition of Atai. Stocks like Compass Pathways, Definium/MindMed, and the PSI ETF stand to benefit significantly.
Thematic ETFs
Long
Jul 23
$212.38
-0.3%
The market-cap-weighted S&P 500 is dangerously concentrated in overvalued mega-cap names. An equal-weighted S&P 500 ETF (RSP) reduces that concentration risk and should outperform as market breadth improves or when the market corrects.
Equity Indexes
Long
Jul 23
$75.12
+0.4%
Gold miners have pulled back sharply while gold remains elevated. The GDX has fallen from ~120 to ~75, P/E multiples contracted significantly, and miners still extract gold at low cost. This divergence creates an attractive entry for a sector that will surge when gold rallies again.
Thematic ETFs
Showing 8 of 8 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Chris Irons has 8 trade ideas tracked on Buzzberg across 8 tickers since July 2026. Ranked #530 on the Buzzberg Alpha leaderboard. Most covered: SPY, GDX, GOLD.
